| Julie A Martin, MD | |
|
8901 W 74th St, Ste 248, Shawnee Mission, KS 66204-2202 | |
| (913) 384-4990 | |
| (913) 384-1310 |
| Full Name | Julie A Martin |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 26 Years |
| Location | 8901 W 74th St, Shawnee Mission, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427054790 | NPI | - | NPPES |
| 100447950A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 04-29515 (Kansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Physician Services Llc | 1658500962 | 39 |
News Archive
Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).
National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.
A group of medical malpractice survivors, many with family members who have died or were severely injured as a result of medical negligence, today sent letters to President Obama and the Congressional leadership urging them to keep additional "tort reforms" out of the health insurance reform bill. They said that responding to pressure from the insurance and medical lobbies to limit patients' legal rights would be a "tragic mistake."
A group of researchers has determined how different proteins associated with SARS-CoV-2 - the virus that causes COVID-19 - generate immune responses when given to rabbits as immunizations.
Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.
› Verified 1 days ago
| Entity Name | Midwest Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952734741 PECOS PAC ID: 1658500962 Enrollment ID: O20140207001686 |
News Archive
Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).
National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.
A group of medical malpractice survivors, many with family members who have died or were severely injured as a result of medical negligence, today sent letters to President Obama and the Congressional leadership urging them to keep additional "tort reforms" out of the health insurance reform bill. They said that responding to pressure from the insurance and medical lobbies to limit patients' legal rights would be a "tragic mistake."
A group of researchers has determined how different proteins associated with SARS-CoV-2 - the virus that causes COVID-19 - generate immune responses when given to rabbits as immunizations.
Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie A Martin, MD 8901 W 74th St, Ste 248, Shawnee Mission, KS 66204-2202 Ph: (913) 384-4990 | Julie A Martin, MD 8901 W 74th St, Ste 248, Shawnee Mission, KS 66204-2202 Ph: (913) 384-4990 |
News Archive
Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).
National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.
A group of medical malpractice survivors, many with family members who have died or were severely injured as a result of medical negligence, today sent letters to President Obama and the Congressional leadership urging them to keep additional "tort reforms" out of the health insurance reform bill. They said that responding to pressure from the insurance and medical lobbies to limit patients' legal rights would be a "tragic mistake."
A group of researchers has determined how different proteins associated with SARS-CoV-2 - the virus that causes COVID-19 - generate immune responses when given to rabbits as immunizations.
Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.
› Verified 1 days ago
Dr. Kimberly Diane Matthews, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9119 W 74th St, Ste 300, Shawnee Mission, KS 66204 Phone: 913-677-3113 Fax: 913-677-4514 | |
Michelle R Dudzinski, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 9301 W 74th St, Suite 130, Shawnee Mission, KS 66204 Phone: 913-632-9130 Fax: 913-632-9149 | |
Brenda Shoup, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9301 W 74th St Ste 130, Shawnee Mission, KS 66204 Phone: 913-632-9130 Fax: 913-632-9149 | |
Lowell J Byers, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9301 W 74th St, Suite 130, Shawnee Mission, KS 66204 Phone: 913-632-9130 Fax: 913-632-9149 | |
Kelsi Maxwell Drummond, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9119 W 74th St Ste 300, Shawnee Mission, KS 66204 Phone: 913-677-3113 | |
Dr. Amy Lynn Giedt, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9119 W 74th St, Suite 300, Shawnee Mission, KS 66204 Phone: 913-677-3113 Fax: 913-677-4514 | |
Dr. Reagan M Wittek, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9119 W 74th St, Suite 300, Shawnee Mission, KS 66204 Phone: 913-677-3113 Fax: 913-677-4514 |